-
Viracta Therapeutics Inc NASDAQ:VIRX Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
Location: 395 Oyster Point Blvd Ste 400, California, 94080-1995, US | Website: www.viracta.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-3.347M
Cash
21.13M
Avg Qtr Burn
-8.699M
Short % of Float
0.79%
Insider Ownership
2.99%
Institutional Own.
29.79%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nana-val (nanatinostat + valganciclovir) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Data readout | |
Nana-val (nanatinostat + valganciclovir) Details Cancer, Lymphoma | Phase 2 Data readout | |
Nana-val (Nanatinostat (VRx-3996) (histone deacetylase (HDAC) inhibitor) + valganciclovir) Details Solid tumor/s, Cancer, Nasopharyngeal carcinoma | Phase 2 Initiation |